REFERENCES
1. Rodriguez T, Lehker A, Mikhailidis DP, Mukherjee D. Carotid artery pathology in inflammatory diseases. Am J Med Sci 2022;363:209-17.
2. Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther 2022;7:131.
3. Pedro-Botet J, Climent E, Benaiges D. Arteriosclerosis e inflamación. Nuevos enfoques terapéuticos. Atherosclerosis and inflammation. New therapeutic approaches. Med Clin 2020;155:256-62.
4. Muller WA. How endothelial cells regulate transmigration of leukocytes in the inflammatory response. Am J Pathol 2014;184:886-96.
5. Cybulsky MI, Cheong C, Robbins CS. Macrophages and dendritic cells: partners in atherogenesis. Circ Res 2016;118:637-52.
6. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res 2014;114:1852-66.
7. Newby AC. Metalloproteinase production from macrophages - a perfect storm leading to atherosclerotic plaque rupture and myocardial infarction. Exp Physiol 2016;101:1327-37.
8. Franck G, Mawson T, Sausen G, et al. Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice: implications for superficial erosion. Circ Res 2017;121:31-42.
9. Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J 2015;36:1394-404.
10. Mouton AJ, DeLeon-Pennell KY, Rivera Gonzalez OJ, et al. Mapping macrophage polarization over the myocardial infarction time continuum. Basic Res Cardiol 2018;113:26.
11. Frangogiannis NG. Inflammation in cardiac injury, repair and regeneration. Curr Opin Cardiol 2015;30:240-5.
12. Higashi Y. Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease. Antioxidants 2022;11:1958.
13. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010;74:213-20.
14. Lavin Plaza B, Phinikaridou A, Andia ME, et al. Sustained focal vascular inflammation accelerates atherosclerosis in remote arteries. Arterioscler Thromb Vasc Biol 2020;40:2159-70.
15. Montarello NJ, Nguyen MT, Wong DTL, Nicholls SJ, Psaltis PJ. Inflammation in coronary atherosclerosis and its therapeutic implications. Cardiovasc Drugs Ther 2022;36:347-62.
16. Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016;118:620-36.
17. Ruparelia N, Choudhury R. Inflammation and atherosclerosis: what is on the horizon? Heart 2020;106:80-5.
18. Gusev E, Sarapultsev A. Atherosclerosis and inflammation: insights from the theory of general pathological processes. Int J Mol Sci 2023;24:7910.
19. Alonso-Herranz L, Albarrán-Juárez J, Bentzon JF. Mechanisms of fibrous cap formation in atherosclerosis. Front Cardiovasc Med 2023;10:1254114.
20. Fernández-Ruiz I. Neutrophil-driven SMC death destabilizes atherosclerotic plaques. Nat Rev Cardiol 2019;16:455.
21. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-75.
22. Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152:1197-206.
23. Martinet W, Schrijvers DM, De Meyer GR. Necrotic cell death in atherosclerosis. Basic Res Cardiol 2011;106:749-60.
24. Oyama J, Blais C Jr, Liu X, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004;109:784-9.
25. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013;34:719-28.
26. Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women: a scientific statement from the american heart association. Circulation 2016;133:916-47.
27. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013;339:161-6.
28. Sager HB, Heidt T, Hulsmans M, et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 2015;132:1880-90.
29. Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J 2022;43:2549-61.
30. Algoet M, Janssens S, Himmelreich U, et al. Myocardial ischemia-reperfusion injury and the influence of inflammation. Trends Cardiovasc Med 2023;33:357-66.
31. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 2014;11:255-65.
32. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 2011;8:292-300.
33. Fullerton JN, O'Brien AJ, Gilroy DW. Pathways mediating resolution of inflammation: when enough is too much. J Pathol 2013;231:8-20.
34. Maruyama K, Imanaka-Yoshida K. The pathogenesis of cardiac fibrosis: a review of recent progress. Int J Mol Sci 2022;23:2617.
35. Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res 2016;365:563-81.
36. Wu L, Xiong X, Wu X, et al. Targeting oxidative stress and inflammation to prevent ischemia-reperfusion injury. Front Mol Neurosci 2020;13:28.
37. Paul TK, Mukherjee D. Is colchicine beneficial for the prevention of cardiovascular events after myocardial infarction? Angiology 2021;72:501-2.
38. Fujisue K, Sugamura K, Kurokawa H, et al. Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. Circ J 2017;81:1174-82.
39. Li YW, Chen SX, Yang Y, et al. Colchicine inhibits NETs and alleviates cardiac remodeling after acute myocardial infarction. Cardiovasc Drugs Ther 2024;38:31-41.
40. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines. Circulation 2023;148:e9-119.
41. Virani SS, Newby LK, Arnold SV, et al. Correction to: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines. Circulation 2023;148:e148.
42. Cataliotti A, Tonne JM, Bellavia D, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation 2011;123:1297-305.
43. González A, Ravassa S, Beaumont J, López B, Díez J. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 2011;58:1833-43.
44. Heinen A, Nederlof R, Panjwani P, et al. IGF1 treatment improves cardiac remodeling after infarction by targeting myeloid cells. Mol Ther 2019;27:46-58.
45. Lin L, Chen L, Yan J, et al. Advances of nanoparticle-mediated diagnostic and theranostic strategies for atherosclerosis. Front Bioeng Biotechnol 2023;11:1268428.
46. Wu Y, Vazquez-Prada KX, Liu Y, Whittaker AK, Zhang R, Ta HT. Recent advances in the development of theranostic nanoparticles for cardiovascular diseases. Nanotheranostics 2021;5:499-514.
47. Boada C, Zinger A, Tsao C, et al. Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation. Circ Res 2020;126:25-37.
48. Boada C, Zinger A, Tsao C, et al. Correction to: Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation. Circ Res 2020;127:e77.
